

Notch Ligands

Introduction

The highly conserved Notch signaling pathway regulates many different cell fate decisions in both vertebrate and invertebrate species [1-4]. It is important for pattern formation during development such as neurogenesis, angiogenesis or myogenesis and regulates T cell development and stem cell maintenance [5-7]. But Notch signaling is also involved in cellular processes throughout adulthood [8]. Signaling via Notch occurs between neighbouring cells and both the receptor and its ligands are transmembrane proteins (see Figure 1).

Notch ligands are single-pass transmembrane proteins with a DSL (Delta, Serrate, LAG-2)-domain and varying numbers of EGF-like repeats. There are two classes of canonical Notch ligands, the Delta/Delta-like and the Serrate/Jagged class. The later has an additional domain of cysteine rich repeats close to the transmembrane domain. There are 5 canonical Notch ligands in mammals: Jagged-1, Jagged-2, DLL1, DLL3 and DLL4. These can bind to the four Notch receptors Notch 1-4.

CONTINUED ON NEXT PAGE




FIGURE 1: Notch Receptors and Their Ligands.

Drosophila contains one Notch receptor (dNotch) that is bound by two transmembrane DSL-ligands (Delta and Serrate). Mammals possess four Notch receptors (Notch1–4) and five ligands (Jagged-1 and -2, which are homologous to Serrate, and Delta-like (DLL) 1, 3 and 4, which are homologous to Delta). Additional non-canonical Notch ligands are Dik1, Dik2 and DNER.

ANK: ankyrin repeats, CR: cysteine-rich domain, DOS: Delta and OSM-11-like proteins domain DSL: Delta, Serrate and LAG-2 domain, EGF: epidermal growth factor-like repeats, LNR: cysteine-rich Lin12-Notch repeats, NLS: nuclear localization signal, P: PEST domain, PM: plasma membrane, R: RAM domain, TAD: transactivation domain. Adapted from: *The intracellular region of Notch ligands: does the tail make the difference?* A. Pintar, et al.; *Biol. Direct* 2, 19 (2007), *The canonical Notch signaling pathway: unfolding the activation mechanism:* R. Kopan & M. X. Ilagan; *Cell* 137, 216 (2009)

In contrast to mammals, *Drosophila* has only two Notch ligands - Delta and Serrate - that can activate the single Notch receptor [9-11].

The noncanonical Notch ligands lack the DSL domain, among these are Dlk1, Dlk2 and DNER [12-15]. Other noncanonical ligands lack all typical Notch ligand domains and can have a completely different structure, some are not even membrane-tethered [16]. They are thought to act as co-ligands to enhance or inhibit Notch activation and might be important modulators of the Notch pathway [14, 16].

Endocytosis of Notch ligands in the signal-producing cells is absolutely required for the initiation of Notch signaling. Two structurally distinct E3 ubiquitin ligases, Neuralized (Neur) and Mind bomb (Mib), are known to regulate the endocytosis of Notch ligands in *Drosophila* and zebrafish, respectively [42, 43]. In mammals, 2 Neur homologs, Neur1 [44, 45] and Neur2 [46], and 2 Mib homologs, Mind bomb-1 (Mib1) [47] and Mib2 [48], have been identified. Although all 4 E3 ubiquitin ligases are known to induce the endocytosis of Notch ligands *in vitro*, only Mib1 has an obligatory role in the activation of Jag- as well as DLL-mediated Notch signaling in mammalian development, while Neur1, Neur2, and Mib2 are dispensable [49].

Upon ligand binding, the Notch receptor is cleaved proteolytically (see Figure 2). This cleavage occurs in a two step-process releasing the extracellular and the intracellular part of Notch

from the membrane. First the extracellular domain with the bound ligand attached to it is released by the action of a ADAM family metalloprotease creating a membrane-bound intermediate called Notch extracellular truncation (NEXT) (S2 cleavage). In a second step, NEXT is cleaved within the transmembrane domain by γ -secretase (S3/S4 cleavage), releasing the Notch intracellular domain (NICD). NICD translocates to the nucleus and with the help of additional enhancers and co-activators activates target genes [10, 17, 18].

Each Notch molecule signals only once without signal amplification by second messengers. This allows a rapid and highly responsive downregulation and reactivation of the signaling pathway. The activity of Notch and its ligands requires endocytosis and is regulated through glycosylation, ubiquitinylation and microRNAs by mechanisms not yet fully understood [19-27].

The Notch pathway plays an important role in many different processes in a wide range of tissues, this is why aberrations in Notch signaling components have been associated with various human disorders such as cancer, immune disorders, developmental syndromes, stroke and cognitive symptoms [10, 28-36]. A mutation in JAG1 can cause the Alagille syndrome [37-39] and other cognitive dysfunctions such as CADASIL or schizophrenia have been associated with mutations of the Notch receptors [40, 41].

FOR LITERATURE REFERENCES SEE PAGE 4




FIGURE 2: The Notch Pathway.

Binding of the Notch ligand (green) on one cell to the Notch receptor (blue) on another cell results in two proteolytic cleavages of the receptor. First a protease of the ADAM family cleaves off most of the extracellular part of Notch leaving a Notch extracellular truncation (NEXT) (S2 cleavage). Second γ -secretase cleaves NEXT at positions S3 and S4 within the transmembrane domain releasing the Notch intracellular domain (NICD). NICD enters the nucleus and interacts with the DNA-binding CSL protein (red), Mastermind (Mam; green) and additional co-activators (Co-A; green). Co-repressors (Co-R; blue and grey) are released and target genes become active.

Adapted from: *Notch signalling: a simple pathway becomes complex*. S. J. Bray; Nat. Rev. Mol. Cell. Biol. 7, 678 (2006). *The canonical Notch signaling pathway: unfolding the activation mechanism*: R. Kopan & M. X. Ilagan; Cell 137, 216 (2009)

DLL1 [Delta-like Protein 1; Delta1]

DLL1 (human) (rec.)

AG-40A-0073-C010 10 µg
AG-40A-0073-C050 50 µg

Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant human DLL1 (aa 1-545) is fused at the C-terminus to a FLAG®-tag.

DLL1 (human):Fc (human) (rec.)

AG-40A-0116-C010 10 µg
AG-40A-0116-C050 50 µg

Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant human DLL1 (aa 1-545) is fused at the C-terminus to the Fc portion of human IgG. Interacts with human Notch1 (as confirmed by flow cytometry).




FIGURE: Interaction of human Notch 1 with DLL1 (human):Fc (human) (rec.) (Prod. No. AG-40A-0116).

METHOD: HEK293 cells transfected with a human Notch 1 or a control vector were incubated with 25µg/ml of GITR (human):Fc (human) (rec.) or DLL1 (human):Fc (human) (rec.) (Prod. No. AG-40A-0116). Cells were stained with anti-human IgG (Fc specific) FITC conjugate for DLL1-Fc binding.

new DLL1 (mouse):Fc (human) (rec.)

AG-40A-0148-C010 10 µg
AG-40A-0148-C050 50 µg

Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant mouse DLL1 (aa 1-545) is fused at the C-terminus to the Fc portion of human IgG. Interacts with Notch receptors.

anti-DLL1 (human), mAb (D1L165-6)

AG-20A-0074-C050 50 µg
AG-20A-0074-C100 100 µg

CLONE: D1L165-6. **ISOTYPE:** Mouse IgG1. **IMMUNOGEN:** Recombinant human DLL1. **SPECIFICITY:** Recognizes human DLL1. **APPLICATION:** WB.

anti-DLL1 (human), pAb

AG-25A-0062-C100 100 µg

From rabbit. **IMMUNOGEN:** Recombinant human DLL1. **SPECIFICITY:** Recognizes human DLL1. **APPLICATION:** IHC (PS), WB.

anti-DLL1 (human), pAb

AG-25A-0079-C100 100 µg

From rat. **IMMUNOGEN:** Recombinant human DLL1. **SPECIFICITY:** Recognizes human DLL1. **APPLICATION:** WB.

DLL3 [Delta-like Protein 3; Delta3]

DLL3 (human):Fc (human) (rec.)

AG-40A-0113-C010 10 µg
AG-40A-0113-C050 50 µg

Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant human DLL3 (aa 1-466) is fused at the C-terminus to the Fc portion of human IgG1.

DLL4 [Delta-like Protein 4; Delta4]

DLL4 (human):Fc (human) (rec.)

AG-40A-0077-C010 10 µg
AG-40A-0077-C050 50 µg

Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant human DLL4 (aa 1-529) is fused at the C-terminus to the Fc portion of human IgG. Interacts with human Notch1 (as confirmed by flow cytometry).




FIGURE: Interaction of human Notch1 with human DLL4 (Prod. No. AG-40A-0077).

METHOD: HEK 293 cells transfected with a human Notch1 or a control vector were incubated with 25µg/ml of GITR (human):Fc (human) (rec.) or DLL4 (human):Fc (human) (rec.) (Prod. No. AG-40A-0077). Cells were stained with anti-human IgG (Fc specific) FITC conjugate for DLL4-Fc binding.

new DLL4 (mouse):Fc (human) (rec.)

AG-40A-0145-C010 10 µg

Produced in HEK 293 cells. Signal peptide and extracellular domain of recombinant mouse DLL4 (aa 1-532) is fused at the C-terminus to the Fc portion of human IgG.

new anti-DLL4 (human), mAb (DL86-3AG)

AG-20A-0080-C050 50 µg
AG-20A-0080-C100 100 µg

CLONE: DL86-3AG. **ISOTYPE:** Mouse IgG1. **IMMUNOGEN:** Recombinant human DLL4 (ectodomain). **SPECIFICITY:** Recognizes human DLL4. **APPLICATION:** WB.

anti-DLL4 (human), pAb

AG-25A-0080-C100 100 µg

From rat. **IMMUNOGEN:** Recombinant human DLL4. **SPECIFICITY:** Recognizes human DLL4. **APPLICATION:** WB.

new DLL1, Soluble (human) ELISA Kit

AG-45A-0027EK-KI01 96 wells
AG-45A-0027TP-KI01 Twin Plex 2 x 96 wells
AG-45A-0027PP-KI01 Penta Plex 5 x 96 wells

For the quantitative determination of soluble DLL1 in human serum, plasma or cell culture supernatant. **SENSITIVITY:** 120pg/ml (range 0 to 16ng/ml).



LITERATURE REFERENCES:

- [1] Notch signalling in *Drosophila*: three ways to use a pathway: S. Bray; *Semin. Cell Dev. Biol.* **9**, 591 (1998)
- [2] Notch signaling: cell fate control and signal integration in development: S. Artavanis-Tsakonas, et al.; *Science* **284**, 770 (1999)
- [3] Notch signaling: control of cell communication and cell fate: E. C. Lai; *Development* **131**, 965 (2004)
- [4] Notch, a universal arbiter of cell fate decisions: M. Ehebauer, et al.; *Science* **314**, 1414 (2006)
- [5] The role of notch in promoting glial and neural stem cell fates: N. Gaiano & G. Fishell; *Annu. Rev. Neurosci.* **25**, 471 (2002)
- [6] Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis: Z. J. Liu, et al.; *Mol. Cell. Biol.* **23**, 14 (2003)
- [7] Notch signaling in development and cancer: V. Bolos, et al.; *Endocr. Rev.* **28**, 339 (2007)
- [8] Regulation of vascular morphogenesis by Notch signaling: C. Roca & R. H. Adams; *Genes Dev.* **21**, 2511 (2007)
- [9] The intracellular region of Notch ligands: does the tail make the difference?: A. Pintar, et al.; *Biol. Direct* **2**, 19 (2007)
- [10] Notch signalling: a simple pathway becomes complex: S. J. Bray; *Nat. Rev. Mol. Cell Biol.* **7**, 678 (2006)
- [11] The Notch gospel: F. Radtke, et al.; *EMBO Rep.* **6**, 1120 (2005)
- [12] DNER acts as a neuron-specific Notch ligand during Bergmann glial development: M. Eiraku, et al.; *Nat. Neurosci.* **8**, 873 (2005)
- [13] The atypical mammalian ligand Delta-like homologue 1 (Dlk1) can regulate Notch signalling in *Drosophila*: S. J. Bray, et al.; *BMC Dev. Biol.* **8**, 11 (2008)
- [14] dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats: V. Baladron, et al.; *Exp. Cell Res.* **303**, 343 (2005)
- [15] The novel gene EGFL9/Dlk2, highly homologous to Dlk1, functions as a modulator of adipogenesis: M. L. Nueda, et al.; *J. Mol. Biol.* **367**, 1270 (2007)
- [16] The many facets of Notch ligands: B. D'Souza, et al.; *Oncogene* **27**, 5148 (2008)
- [17] An overview of the Notch signalling pathway: M. Baron; *Semin. Cell Dev. Biol.* **14**, 113 (2003)
- [18] The canonical Notch signaling pathway: unfolding the activation mechanism: R. Kopan & M. X. Ilagan; *Cell* **137**, 216 (2009)
- [19] The roles of receptor and ligand endocytosis in regulating Notch signaling: R. Le Borgne, et al.; *Development* **132**, 1751 (2005)
- [20] The interplay between DSL proteins and ubiquitin ligases in Notch signaling: C. Pitsouli & C. Delidakis; *Development* **132**, 4041 (2005)
- [21] Notch signaling: endocytosis makes delta signal better: R. Le Borgne & F. Schweisguth; *Curr. Biol.* **13**, R273 (2003)
- [22] Functions of O-fucosyltransferase in Notch trafficking and signaling: towards the end of a controversy?: N. Vodovar & F. Schweisguth; *J. Biol.* **7**, 7 (2008)
- [23] Glycosylation regulates Notch signalling: N. Haines & K. D. Irvine; *Nat. Rev. Mol. Cell Biol.* **4**, 786 (2003)
- [24] MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes: Y. Li, et al.; *Cancer Res.* **69**, 7569 (2009)
- [25] MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells: Q. Ji, et al.; *PLoS One* **4**, e6816 (2009)
- [26] MicroRNA1 influences cardiac differentiation in *Drosophila* and regulates Notch signaling: C. Kwon, et al.; *PNAS* **102**, 18986 (2005)
- [27] MicroRNA regulation of cell lineages in mouse and human embryonic stem cells: K. N. Ivey, et al.; *Cell Stem Cell* **2**, 219 (2008)
- [28] Notch signaling in cancer: L. Miele, et al.; *Curr. Mol. Med.* **6**, 905 (2006)
- [29] NOTCH signaling as a novel cancer therapeutic target: L. Miele, et al.; *Curr. Cancer Drug Targets* **6**, 313 (2006)
- [30] Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia: A. P. Weng, et al.; *Science* **306**, 269 (2004)
- [31] The role of Notch in tumorigenesis: oncogene or tumour suppressor?: F. Radtke & K. Raj; *Nat. Rev. Cancer* **3**, 756 (2003)
- [32] Notch signalling pathway and human diseases: A. Joutel & E. Tournier-Lasserre; *Semin. Cell Dev. Biol.* **9**, 619 (1998)
- [33] Recent insights into the role of Notch signaling in tumorigenesis: K. G. Leong & A. Karsan; *Blood* **107**, 2223 (2006)
- [34] Notch and cancer: a double-edged sword: U. Koch & F. Radtke; *Cell. Mol. Life Sci.* **64**, 2746 (2007)
- [35] Abnormal vertebral segmentation and the notch signaling pathway in man: P. D. Turnpenny, et al.; *Dev. Dyn.* **236**, 1456 (2007)
- [36] Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis: M. P. Bulman, et al.; *Nat. Genet.* **24**, 438 (2000)
- [37] Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1: L. Li, et al.; *Nat. Genet.* **16**, 243 (1997)
- [38] Mutations in the human Jagged1 gene are responsible for Alagille syndrome: T. Oda, et al.; *Nat. Genet.* **16**, 235 (1997)
- [39] Alagille syndrome and the Jagged1 gene: D. A. Piccoli & N. B. Spinner; *Semin. Liver Dis.* **21**, 525 (2001)
- [40] Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia: A. Joutel, et al.; *Nature* **383**, 707 (1996)
- [41] NOTCH4 and the frontal lobe in schizophrenia: T. H. Wassink, et al.; *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **118B**, 1 (2003)
- [42] neuralized Encodes a peripheral membrane protein involved in delta signaling and endocytosis: E. Pavlopoulos, et al.; *Dev. Cell* **1**, 807 (2001)
- [43] Mind bomb is a ubiquitin ligase that is essential for efficient activation of Notch signaling by Delta: M. Itoh, et al.; *Dev. Cell* **4**, 67 (2003)
- [44] Ethanol hypersensitivity and olfactory discrimination defect in mice lacking a homolog of *Drosophila* neuralized: Y. Ruan, et al.; *PNAS* **98**, 9907 (2001)
- [45] Isolation of a murine homologue of the *Drosophila* neuralized gene, a gene required for axonemal integrity in spermatozoa and terminal maturation of the mammary gland: B. Vollrath, et al.; *Mol. Cell. Biol.* **21**, 7481 (2001)
- [46] Neuralized-2 regulates a Notch ligand in cooperation with Mind bomb-1: R. Song, et al.; *J. Biol. Chem.* **281**, 36391 (2006)
- [47] Mind bomb 1 is essential for generating functional Notch ligands to activate Notch: B.K. Koo, et al.; *Development* **132**, 3459 (2005)
- [48] Mind bomb-2 is an E3 ligase for Notch ligand: B.K. Koo, et al.; *J. Biol. Chem.* **280**, 22335 (2005)
- [49] An obligatory role of mind bomb-1 in notch signaling of mammalian development: B.K. Koo, et al.; *PLoS One* **2**, e1221 (2007)

SELECTED LATEST REVIEW ARTICLES

- The role of Notch in patterning the human vertebral column: S. L. Dunwoodie; *Curr. Opin. Genet. Dev.* **19**, 329 (2009)
- Notch signaling: the core pathway and its posttranslational regulation: M. E. Fortini; *Dev. Cell* **16**, 633 (2009)
- Notch: A new player in MS mechanisms: M. Jurynczyk & K. Selmaj; *J. Neuroimmunol.* **Epub ahead of print**, (2009)
- The molecular logic of Notch signaling—a structural and biochemical perspective: W. R. Gordon, et al.; *J. Cell Sci.* **121**, 3109 (2008)
- The canonical Notch signaling pathway: unfolding the activation mechanism: R. Kopan & M. X. Ilagan; *Cell* **137**, 216 (2009)
- Notch: from neural development to neurological disorders: J. D. Lathia, et al.; *J. Neurochem.* **107**, 1471 (2008)
- ADAM proteases: ligand processing and modulation of the Notch pathway: A. Zolkiewska; *Cell. Mol. Life Sci.* **65**, 2056 (2008)
- A Notch updated: A. C. Tien, et al.; *J. Cell Biol.* **184**, 621 (2009)
- The many facets of Notch ligands: B. D'Souza, et al.; *Oncogene* **27**, 5148 (2008)
- Intracellular trafficking of Notch receptors and ligands: C. Brou; *Exp. Cell Res.* **315**, 1549 (2009)
- Endocytic regulation of Notch signaling: M.E. Fortini & D. Bilder; *Curr. Opin. Genet. Dev.* **19**, 323 (2009)
- Notch activity in the nervous system: to switch or not switch?: E. Cau & P. Blader; *Neural. Dev.* **4**, 36 (2009)
- Notch signalling and haematopoietic stem cell formation during embryogenesis: M. Gering & R. Patient; *J. Cell Physiol.* **222**, 11 (2010)

Dlk1 [Delta-like Protein; Pref-1]

Dlk1 (human) (rec.)

AG-40A-0133-C010 10 µg
AG-40A-0133-C050 50 µg

Produced in HEK 293 cells. The signal peptide and the extracellular domain of human Dlk1 (aa 1-303) is fused at the C-terminus to a FLAG®-tag.

Dlk1 (human):Fc (human) (rec.)

AG-40A-0118-C010 10 µg
AG-40A-0118-C050 50 µg

Produced in HEK 293 cells. The signal peptide and the extracellular domain of human Dlk1 (aa 1-303) is fused at the C-terminus to the Fc portion of human IgG.

Dlk1 (mouse):Fc (human) (rec.)

AG-40A-0107-C010 10 µg
AG-40A-0107-C050 50 µg

Produced in HEK 293 cells. The signal peptide and the extracellular domain of mouse Dlk1 (aa 1-305) is fused at the C-terminus to the Fc portion of human IgG.

anti-Dlk1 (human), mAb (PF13-3)

AG-20A-0069-C050 50 µg
AG-20A-0069-C100 100 µg

CLONE: PF13-3. ISOTYPE: Mouse IgG1. IMMUNOGEN: Recombinant human Dlk1 (extracellular domain). SPECIFICITY: Recognizes human Dlk1. APPLICATION: FC, IHC, WB.

anti-Dlk1 (human), mAb (PF299-1)

AG-20A-0070-C050 50 µg
AG-20A-0070-C100 100 µg

CLONE: PF299-1. ISOTYPE: Mouse IgG1. IMMUNOGEN: Recombinant human Dlk1 (extracellular domain). SPECIFICITY: Recognizes human Dlk1. APPLICATION: FC, IHC, WB.

anti-Dlk1 (mouse), mAb (PF105B)

AG-20A-0057-C050 50 µg
AG-20A-0057-C100 100 µg

CLONE: PF105B. ISOTYPE: Rat IgG2. IMMUNOGEN: Recombinant mouse Dlk1 (extracellular domain). SPECIFICITY: Recognizes mouse Dlk1. APPLICATION: WB.

anti-Dlk1 (mouse), mAb (PF183E)

AG-20A-0058-C050 50 µg
AG-20A-0058-C100 100 µg

CLONE: PF183E. ISOTYPE: Rat IgG2. IMMUNOGEN: Recombinant mouse Dlk1 (extracellular domain). SPECIFICITY: Recognizes mouse Dlk1. APPLICATION: WB.

new anti-Dlk1 (human), pAb

AG-25A-0092-C100 100 µg

From rabbit. IMMUNOGEN: Recombinant human Dlk1 (extracellular domain). SPECIFICITY: Recognizes human Dlk1. Weakly cross-reacts with mouse Dlk1. APPLICATION: WB.

anti-Dlk1 (human), pAb

AG-25A-0091-C100 100 µg

From rat. IMMUNOGEN: Recombinant human Dlk1 (extracellular domain). SPECIFICITY: Recognizes human Dlk1. APPLICATION: FC, WB.

LATEST INSIGHT

Notch Ligands Inhibit Adipocyte Differentiation

Not only Dlk1/Pref-1 [Y. Wang & H.S. Sul; Cell Metab. 9, 287 (2009)] but also the human Notch ligands DLL1, DLL4, DNER have been shown to inhibit adipocytes differentiation (adipogenesis) [unpublished data], therefore being interesting tools for stem cell research.

Experimental: Adipogenesis Inhibition

3T3L1 cells were maintained in DMEM supplemented with 10% FBS and penicillin-streptomycin. When the cells were confluent grown, adipogenesis was initiated by adding IBMX, dexamethasone, and insulin to 0.5mM, 1µM, and 10µg/ml, respectively and continued for 2 days (day 0). The medium was replaced every 2 days with new medium containing insulin in the presence or absence of 5µg/ml of each human recombinant Notch ligand-Fc fusion protein (human DLL1-Fc, human DNER-Fc, or human Dlk1/Pref-1) and human CD137-Fc as a control-Fc. Staining with Oil Red O was typically performed on day 7.




FIGURE 1: Adipogenesis inhibition of 3T3L1 cells by DLL1 (human):Fc (human) (rec.) (Prod. No. AG-40A-0116).




FIGURE 2: Adipogenesis inhibition of 3T3L1 cells by DNER (extracellular domain) (human):Fc (human) (rec.) (Prod. No. AG-40A-0119).

Jagged-1 [HJ1; CD338]

Jagged-1 (human):Fc (human) (rec.)

AG-40A-0081-C010 10 µg
AG-40A-0081-C050 50 µg
Produced in HEK 293 cells. Signal peptide and extracellular domain of human Jagged-1 (HJ1; CD338) (aa 1-1067) are fused at the C-terminus to the Fc portion of human IgG.




FIGURE: Differentiation of human mesenchymal stem cells (MSCs) into adipocytes in the presence or absence of Notch ligands that inhibit adipogenic differentiation of MSCs.

METHOD: MSCs were maintained in DMEM, supplemented with 10% fetal bovine serum, penicillin-streptomycin and glutamine. For differentiation of MSCs they were cultured in adipogenic medium corresponding to growth medium supplemented with 1µM dexamethasone, 0.5mM IBMX, 10µg/ml insulin and 100µM indomethacin (day 1). Medium was changed every 3 days. Staining with Oil Red O was typically performed on day 30. For negative controls TNF-α (20ng/ml) was added. To immobilize Notch ligands on the plastic surface of the culture plates, plates were incubated with a solution of Jagged-1 (human):Fc (human) (rec.) (Prod. No. AG-40A-0081) (5µg/ml) or CD137L:Fc (5µg/ml) in PBS for 2 hours at 37°C. These plates were then used to differentiate MSCs.

anti-Jagged-1 (human), mAb (J1G74-7)

AG-20A-0050-C100 100 µg
CLONE: J1G74-7. **ISOTYPE:** Mouse IgG1. **IMMUNOGEN:** Recombinant human Jagged-1. **SPECIFICITY:** Recognizes human Jagged-1. **APPLICATION:** FC, WB.

anti-Jagged-1 (human), pAb

AG-25A-0081-C100 100 µg
From rat. **IMMUNOGEN:** Recombinant human Jagged-1 (extracellular domain). **SPECIFICITY:** Recognizes the extracellular domain and full-length human Jagged-1. **APPLICATION:** WB.

anti-Jagged-1 (human), mAb (J1G53-3)

AG-20A-0049-C100 100 µg
AG-20A-0049F-C050 FITC 50 µg
AG-20A-0049PC-C050 PerCP 50 µg

CLONE: J1G53-3. **ISOTYPE:** Mouse IgG1. **IMMUNOGEN:** Recombinant human Jagged-1. **SPECIFICITY:** Recognizes human Jagged-1. **APPLICATION:** FC, WB.




FIGURE: Flow Cytometry. Surface staining method was used to stain normal human peripheral blood cells (CD4⁺ selections) with anti-Jagged-1 (human), mAb (J1G53-3) (FITC). An appropriate isotype control was used for FITC mouse IgG1.




FIGURE: Flow Cytometry.

A: Surface staining method was used to stain normal human peripheral blood cells (CD4⁺ selections) with anti-Jagged-1 (human), mAb (J1G53-3) (PerCP). An appropriate isotype control was used for PerCP mouse IgG1.

B: Human CD4⁺ (selected via DYNAL113.03) cells were surface-stained with cocktail of CD4-FITC and CD25-PE subsequently with 20µl/million cells anti-Jagged-1 (human), mAb (J1G53-3) (PerCP) or PerCP mouse IgG1 isotype control using the human regulatory T cell staining set. The dot plot on the left demonstrates co-staining of CD4 and CD25, while the histogram on the right demonstrates J1G53-3 staining of gated CD4⁺ CD25⁺ lymphocytes (Regulatory T cells / Treg) versus isotype control. Cells in the lymphocyte gate were used for flow cytometric analysis.

DNER

DNER (extracellular domain) (human) (rec.)

AG-40A-0137-C010 10 µg
AG-40A-0137-C050 50 µg
Produced in HEK 293 cells. The signal peptide and the extracellular domain of human DNER (aa 1-640) are fused at the C-terminus with a FLAG[®]-tag.

DNER (extracellular domain) (human):Fc (human) (rec.)

AG-40A-0119-C010 10 µg
AG-40A-0119-C050 50 µg
Produced in HEK 293 cells. The signal peptide and the extracellular domain of human DNER (aa 1-637) is fused at the C-terminus to the Fc portion of human IgG.

new anti-DNER (human), mAb (DR324-4)

AG-20A-0078-C050 50 µg
AG-20A-0078-C100 100 µg

CLONE: DR324-4. **ISOTYPE:** Mouse IgG2. **IMMUNOGEN:** Recombinant human DNER (ectodomain). **SPECIFICITY:** Recognizes human DNER. **APPLICATION:** WB.

new anti-DNER (human), pAb

AG-25A-0102-C100 100 µg
From rabbit. **IMMUNOGEN:** Recombinant human DNER (ectodomain). **SPECIFICITY:** Recognizes human DNER. **APPLICATION:** WB.

AdipoGenTM
Connecting Immunology to MetabolismTM
www.adipogen.com

EUROPE/REST OF WORLD
Adipogen International
TEL +41-61-926-60-40
FAX +41-61-926-60-49
info@adipogen.com

NORTH & SOUTH AMERICA
Adipogen Corp.
TEL +1-858-457-8383
FAX +1-858-457-8484
info-us@adipogen.com

SOUTH KOREA/ASIA
Adipogen, Inc.
TEL +82-32-858-1470
FAX +82-32-831-1470
info-kr@adipogen.com

For local distributors please visit our website.